

Grand Venture Technology Limited

13 August 2021

HOLD (Downgrade)

Price: S\$1.230 (as at 12 August 2021)

Target Price: S\$1.300 (+5.7%)

BBG	GVTL SP
Market cap	S\$376.1 million
Price (12 August 2021)	S\$1.230
52-week range	S\$0.245 – S\$1.340
Target Price	S\$1.300
Shares Outstanding	305.8 million
Free Float	21.04%
Major Shareholder	Metalbank Singapore 31.1% Novo Tellus SPV12 29.6% Sunshine Power 9.2%
P/BV (06/21)	5.5x

2.3x

Source: Company data, Bloomberg, SAC Capital

Net Debt to EBITDA (12/20)

Analyst

Lim Li Jun Tracy +65 6232 3239 tlim@saccapital.com.sg

Growth in all segments

1H revenue almost doubled. The Group recorded a 98.9% yoy increase in 1HFY21 revenue from S\$26.9m to S\$53.5m, which made up 87.2% of total FY20 revenue. Net profit was up 3.8x, from S\$2.2m to S\$8.5m, pulled up by a growing share of customers. Demand in all 3 segments were strong, with semiconductor segment seeing strongest growth again (+72.6% to S\$38.9m), life sciences segment (+15.4% to S\$8.3m) and electronics, medical and others (+12.0% to S\$6.4m).

Malaysia's Movement Control Order, however, restricted some operations in Penang during 1H. As some states of Malaysia, including Penang, moves out of MCO towards their National Recovery Plan, we expect operations will improve.

Expanded Malaysia facility. The Penang factory bought in March is expected to add ~38% to Malaysia capacity and ~20% to total capacity, which we expect will contribute gradually from 4Q. We continue to expect higher ROIC for the coming 2 FYs, from the 9.1% figure in FY20, especially seeing that orderbook is strong and limiting factor lies in production capacity.

Maintained our FY21 and FY22 topline estimates. Bottomline estimates see marginal adjustments (+0.4% and +5.2% respectively) with lower forecasted expenses (SG&A costs) considering the high fixed cost nature, but accounting for higher effective tax rates (to 18% from 13.5%) going forward. GVT also announced its first payout of a 0.5 cents/share interim dividend.

Downgrade to HOLD, at fair value of \$\$1.30. Our DCF-derived target price translates into a FY21E/FY22E P/E of 27.5x and 22.2x respectively. Our target price implies a 5.7% upside to the last traded price. We noted that GVT's P/E is higher than average, but we see potential in its growth with the placement proceeds (net \$\$23.5m) and support from Novo Tellus, its strong customer base and its differentiated capabilities. We are also cautious of Malaysia's elevated Covid cases, Singapore's manpower supply crunch, and China's resurgence of cases in some cities which may cause supply chain disruptions.

Key Risks: Supply chain disruptions, key customer risks

Key Financials

1toy i manolalo					
FY ended 31 Dec	FY2018	FY2019	FY2020	FY2021E	FY2022E
Revenue (S\$'m)	41.0	40.1	61.4	99.4	130.5
EBIT (S\$'m)	6.8	4.9	7.4	18.9	23.5
Net profit (S\$'m)	4.7	3.1	5.2	14.5	17.9
Basic EPS (S cents)	2.67	1.34	2.23	4.73	5.86
Dividend per share (S cents)	-	-	-	0.50	0.95
Net cash / (debt)	(16.3)	(15.7)	(32.2)	(9.8)	(3.2)
Valuation					
EBIT margin (%)	16.6	12.3	12.1	19.0	18.0
ROIC (%)	14.8	7.2	9.1	18.0	20.1
EV/EBITDA (x)	37.3	40.2	28.8	14.2	11.4
P/E (x) *	46.1	91.8	55.2	26.0	21.0
Dividend yield (%)	-	-	-	0.4	0.8

^{*} Based on weighted average shares at that period.



Investment Summary

1H revenue almost doubled

The Group recorded a 98.9% yoy increase in 1HFY21 revenue from \$\$26.9m to \$\$53.5m, which made up 87.2% of total FY20 revenue. Net profit was up 3.8x, from \$\$2.2m to \$\$8.5m, pulled up by a growing share of customers.

Demand in all 3 segments were strong, with semiconductor segment seeing strongest growth again (+72.6% to S\$38.9m) in line with the global high demand and shortage of semiconductor chips. Life sciences segment (+15.4% to S\$8.3m) was driven by increased mass production of mass spectrometers subsequent to receiving customers' qualifications, and the higher industry demand for such equipment. The last segment, electronics, medical and others (+12.0% to S\$6.4m) with higher demand for electronics products and an increased penetration to the medical sector.

Group gross margin increased to 33.1% in 1H, from 29.8% a year ago, mainly due to improved capacity utilization from last year's restricted measures which led to factories shutting down and supply chain disruptions. Malaysia's Movement Control Order (MCO) however, restricted some operations in Penang during 1H. As some states of Malaysia, including Penang, moves out of MCO towards their National Recovery Plan (NRP), we expect operations will improve.

Expanded Malaysia facility, expected to add ~20% to total capacity

GVT allocated S\$8.0m of placement proceeds (net S\$23.5m) towards capex, which they had used to buy a Penang factory in March, adding ~38% to Malaysia capacity and ~20% to total capacity across all 3 countries. Taking into consideration renovations, we expect the new factory to begin production in 4QFY21 or 1QFY22, and be ramped up to higher capacity later in FY22.

Country	Location	Land Area	Activities
Singapore	Changi North	86,736 sq ft	Corporate Headquarters Precision Machining Assembly and Testing
Malaysia	Penang	169,480 sq ft + 65,076 sq ft* floor area	Precision Machining Sheet Metal Fabrication Assembly and Testing
China	Suzhou	63,000 sq ft	Precision Machining Assembly and Testing
Total area		319,216 sqft	

^{*} Will be undergoing renovation before adding to capacity

Source: Company data

We continue to expect higher ROIC at least for the coming 2 FYs, from the 9.1% figure in FY20, especially seeing that orderbook is strong and limiting factor lies in production capacity.

 Revenue (S\$'m)
 1H21
 1H20

 Semi-conductor
 38.9
 18.2

 Life sciences
 8.3
 5.1

6.4

53.5

3.6

26.9

Source: Company data

Electronics.

medical &

others

Total



Investment Summary

Growing capabilities

Given their competencies in ultra precision machining and advanced materials machining, GVT is expanding its revenue streams to develop in-house competencies in advanced materials (specifically, quartz and ceramic). Management believes these advanced materials will open a gateway into more niche products in the market, especially as they possess the capabilities required for production. Given the challenging technologies required, less competition can be anticipated.

Strong and sticky customer base

Given its customers' market share and presence, solid market demand is expected to translate to firmer toplines. The Group serves some of the largest OEMs, having 4 of the top 6 semiconductor back-end suppliers as their customers, and they also have 3 in the top 10 analytical life sciences players as customers. Management also said that cross-selling opportunities are present, within and across industry verticals.

Downgrade to HOLD, at fair value of S\$1.30.

Our DCF-derived target price translates into a FY21E/FY22E P/E of 27.5x and 22.2x respectively. Our target price implies a 5.7% upside to the last traded price.

We maintained our FY21 and FY22 topline estimates. Bottomline estimates see marginal adjustments (+0.4% and +5.2% respectively) with lower forecasted expenses (selling, distribution, and general and administrative costs) considering the high fixed cost nature, but accounting for higher effective tax rates (to 18% from 13.5%) going forward. GVT also announced its first payout of a 0.5 cents/share interim dividend.

We expect strong demand in all segments will continue, with the global semiconductor super cycle, higher demand in the mass spectrometry market amid higher testing activity, and the increased penetration into the medical sector. Higher vaccination rates are pointing to less restrictive border measures. However, we are still cautious of Malaysia's elevated Covid cases, Singapore's manpower supply crunch, and China's resurgence of cases in some cities which may cause supply chain disruptions.

We noted that GVT's P/E is higher than average, but we see potential in its growth with the placement proceeds (net S\$23.5m) and support from Novo Tellus, its strong customer base and its differentiated capabilities.

TICKER	Market Cap (SGD mil)	P/E (as at 12 Aug 2021)
AEM HOLDINGS LTD	1,150.89	15.71
UMS HOLDINGS LTD	938.84	22.80
FRENCKEN GROUP LTD	922.33	16.70
MICRO-MECHANICS HOLDINGS LTD	446.29	25.93
GRAND VENTURE TECHNOLOGY	376.11	28.29
ISDN HOLDINGS LTD	350.45	19.76
INNOTEK LTD	209.36	14.93
AVI-TECH ELECTRONICS LTD	70.13	17.43
ASTI HOLDINGS LTD	23.19	10.76
SECTOR AVERAGE	498.62	19.14



Income Statement

		Fiscal Y	ear Endec	31 Dec	
S\$'mil	FY2018A	FY2019A	FY2020A	FY2021E	FY2022E
Revenue	41.0	40.1	61.4	99.4	130.5
Cost of sales	-26.2	-25.2	-42.5	-66.0	-88.3
Gross profit	14.8	14.9	18.9	33.4	42.3
Other income	1.3	0.6	0.5	0.5	0.5
Selling and distribution costs	-0.6	-0.5	-0.5	-0.8	-1.2
General and administrative expenses	-6.9	-8.1	-9.6	-11.5	-13.8
Other operating expenses	-1.7	-2.0	-2.0	-2.7	-4.2
Profit before tax	5.9	3.8	6.0	17.6	22.1
Tax expense	-1.2	-0.7	-0.8	-3.2	-4.2
Profit/(loss) for the year	4.7	3.1	5.2	14.5	17.9

Ratios

		Fiscal Y	ear Endec	l 31 Dec	
	FY2018A	FY2019A	FY2020A	FY2021E	FY2022
Profitability (%)					
Gross profit/(loss) margin	36.2	37.2	30.8	33.6	32.4
Profit/(loss) before tax margin	14.4	9.6	9.8	17.7	16.9
Liquidity (x)					
Current ratio Quick ratio Interest coverage ratio Net Debt to Equity (%) Valuation (x)	1.1 0.6 7.3 136.5	1.5 0.8 4.5 65.7	1.9 1.1 5.2 87.4	2.8 1.9 14.8 13.4	3.0 2.0 16.3 3.6
P/E P/B EV/EBITDA	46.1 13.5 37.3	91.8 9.0 40.2	55.2 7.8 28.8	26.0 5.1 14.2	21.0 4.3 11.4
Cash Conversion Cycle					
Trade receivable days Inventory days Trade payable days CCC days	85 148 150 82	118 228 155 191	106 180 113 173	72 127 80 119	61 105 66 99

Balance Sheet

	Fiscal Year Ended 31 Dec				
S\$'mil	FY2018A	FY2019A	FY2020A	FY2021E	FY2022E
Property, plant and equipment	24.1	34.7	43.3	56.3	62.4
Intangible assets Prepayment	2.1 0.3	2.0 0.6	2.0 0.0	2.0 0.0	2.0 0.0
Deferred tax assets	1.2	1.1	1.0	0.7	0.7
Total non-current assets	27.6	38.4	46.4	59.0	65.1
Cash and bank balances	2.5	5.8	7.5	25.9	29.0
Trade and other receivables	9.6	13.0	17.9	19.7	21.6
Prepayments	1.1	0.7	1.7	1.7	1.7
Inventories	10.6	15.7	20.9	23.0	25.3
Total current assets	23.7	35.2	48.0	70.3	77.6
Total assets	51.3	73.6	94.4	129.3	142.7
Loans and borrowings	14.1	14.2	29.1	26.2	23.6
Lease liabilities	0.0	3.9	3.4	4.7	5.2
Others Total non-current	0.0	0.0	0.2	0.2	0.2
liabilities	14.1	18.1	32.8	31.2	29.0
Trade and other payables	10.8	10.7	13.2	14.5	16.0
Loans and borrowings	10.3	12.3	10.6	9.5	8.6
Lease liabilities	0.0	0.7	0.7	0.8	0.8
Others Total current liabilities	0.1 21.2	0.3 24.0	0.3 24.8	0.3 25.1	0.3 25.6
	21.2	24.0	24.6	25.1	25.6
Total liabilities	35.3	42.1	57.5	56.3	54.7
Share Capital	15.4	27.8	27.8	51.3	51.3
Currency translation reserve	-0.9	-1.0	-0.9	-1.1	-1.1
Retained earnings	1.6	4.7	9.9	22.8	37.8
Total equity	16.1	31.5	36.9	73.1	88.1
Total liabilities and equity	51.3	73.6	94.4	129.3	142.7

Cash Flows Statement

		Fiscal V	ear Ended	l 21 Doc	
	EVO040A				EVACCE
S\$'mil	FY2018A I		FY2U2UA	FYZUZTE	FYZUZZE
Cash flows from operating	g activities 5.9	3.8	6.0	17.6	22.1
Profit/(loss) before tax	5.9	3.8	6.0	17.6	22.1
Depreciation and amortisation	3.7	4.8	6.7	8.2	9.8
Interest expense	0.0	0.0	0.0	0.0	0.0
Interest expense	0.0	1.1	1.4	1.3	1.4
Unrealised forex gain	-0.1	-0.2	-0.1	0.0	0.0
Others	0.1	0.0	0.1	0.0	0.0
OCF before changes in					
working capital	10.5	9.5	14.3	27.1	33.4
Changes in working capital	-2.5	-8.8	-8.3	-2.6	-2.8
Income taxes paid	-0.7	-0.6	-0.7	-3.2	-4.2
Interest received	0.0	0.0	0.0	0.0	0.0
Interest paid	-0.9	-1.3	-1.4	-1.3	-1.4
Net cash from operating	-0.9		-1	-1.5	-1.4
activities	6.3	-1.2	4.0	20.1	24.9
Cash flows from investin	a activities				
Purchase of PPE	-5.2	-6.0	-7.4	-14.3	-9.3
PPE disposal proceeds	0.0	0.0	0.0	0.0	0.0
Capital expenditure grant					
received	0.0	0.3	0.1	0.0	0.0
Net cash outflow on	0.0	0.0	0.0	0.0	0.0
acquisition of business	-0.8	0.0	0.0	0.0	0.0
Net cash used in	-5.9	-5.7	-7.3	-14.3	-9.3
investing activities	-5.9	-5.7	-7.3	-14.3	-9.3
Cash flows from financin	g activities				
Dividends paid	0.0	0.0	0.0	-1.5	-2.9
Proceeds from borrowings	5.3	2.1	25.4	3.2	3.2
Repayment of borrowings	-3.3	-2.6	-15.8	-7.2	-6.8
Repayment of hire	-2.5	-2.4	-3.6	-4.4	-5.1
purchases	-2.5	-2.4	-3.0	-4.4	-5.1
Payment of principal	0.0	-0.3	-0.7	-0.9	-1.0
portion of lease liabilities		0.0	0.7	0.5	1.0
Proceeds from issuance of	1.2	13.2	0.0	23.5	0.0
shares					
Others	-0.4	0.5	-0.4	0.0	0.0
Net cash (used in)/from	0.2	10.5	5.0	12.7	-12.6
financing activities					
Net increase in cash	0.6	3.6	1.6	18.5	3.0
Forex effects	0.0	0.0	0.1	0.0	0.0
Beginning cash	1.2	1.8	5.4	7.1	25.6
Ending Cash	1.8	5.4	7.1	25.6	28.6
Lituding Cash	1.0	J. 4	7.1	23.0	20.0

^{*} Cash and bank balances include cash and short-term fixed deposits.



DISCLAIMERS AND DISCLOSURES

This report has been prepared and distributed by SAC Capital Private Limited ("SAC Capital") which is a holder of a capital markets services licence and an exempt financial adviser in Singapore.

This report has been prepared for the purpose of general circulation, we have not had regard to the specific investment objectives, financial situation, tax position or unique needs and constraints of any individual person or any specific group of persons and does not purport to be comprehensive or contain all necessary information which a prospective investor may require in arriving at an investment decision. Any prospective purchaser should make his own investigation of the securities and all information provided. Advice should be sought from a financial adviser regarding suitability, taking into account the specific investment objectives, financial situation or particular needs of the person in receipt of the recommendation, before a commitment to purchase is entered into.

This report does not constitute or form part of any offer or solicitation of any offer to buy or sell any securities. This report is confidential and the information in this report shall not be copied or reproduced in part or in whole, and save for the recipient of this report, shall not be disclosed to any other person without the prior written consent of SAC Capital. The distribution of this report outside the jurisdiction of Singapore is also strictly prohibited.

Whereas SAC Capital has not independently verified all the information set out in this report, all reasonable care and effort has been taken to ensure that the facts stated herein are accurate, this report might contain certain forward looking statements and forward looking financial information which are based on certain assumptions and involve known and unknown risks, uncertainties and other factors which may cause the actual results or performance of the subject company to be materially different from those expressed herein. Predictions, projections or forecasts of the economy or market trends are not indicative of the future performance of the subject company. The inclusion of such statements and information should not be regarded as a representation, warranty or prediction with respect to the accuracy of the underlying assumptions of the subject company or that the forecast results will or are likely to be achieved.

Our opinion and facts set out in this report are based on the market, economic, industry and other applicable conditions prevailing as at the date of the preparation of this report. Such conditions may change significantly over a relatively short period of time and we assume no responsibility to update, revise or reaffirm our opinion in light of any development subsequent to the publication of this report, that may or may not have affected our opinion contained herein.

This report contains forward-looking statement which are based on assumptions or forecasts and are subject to uncertainties which may result in the actual result or performance to be materially different from the opinion or facts set out herein. Caution should be exercised in placing undue reliance on such statements. such assumptions or forecasts may change over a relatively short period of time and we assume no responsibility to update, revise or reaffirm our opinion in light of any development subsequent to the publication of this report.

No representation or warranty, expressed or implied, is made and no responsibility is accepted by the company, SAC Capital, or any of their affiliates, advisers or representatives as to the fairness, accuracy, completeness or adequacy of such information or facts, in this report or any other written or oral information made available to any interested party or its advisers and any liability therefore is hereby expressly disclaimed.

SAC Capital and its associates, directors, and/or employees may have positions in the securities covered in the report and may also perform or seek to perform other corporate finance and/or capital markets related services for the company whose securities are covered in the report. SAC Capital and its related companies may from time to time perform advisory services or solicit such advisory services from the entity mentioned in this report ("Other Services"). This report is therefore classified as a non-independent report. However, the research professionals involved in the preparation of this report are independent of those possible or actual business relationships as they have not and will not participate in the solicitation or provision of such business.

As at the date of this report, SAC Capital does not have proprietary positions or interests in the subject company, except for:

Party	Quantum of position
Nil	Nil

As at the date of this report, SAC Capital, has had business relations with the subject company within the past 12 months, as disclosed hereunder:

Nature of Business Relation	Date of Business Relation
Nil	Nil



As at the date of this report, none of the analysts who covered the securities in this report have any proprietary position or material interest in the subject companies covered here in, except for:

Analyst name	Quantum of position
Nil	Nil

ANALYST CERTIFICATION/REGULATION AC

As noted above, research analyst(s) of SAC Capital who produced this report hereby certify that

- (i) The views expressed in this report accurately reflect his/her personal views about the subject corporation(s);
- (ii) The report was produced independently by him/her;
- (iii) He/she does not on behalf of SAC Capital or any other person carry out Other Services involving any of the subject corporation(s) or securities referred to in this report; and
- (iv) He/she has not received and will not receive any compensation directly or indirectly related to the recommendations or views expressed in this report or to any sales, trading, dealing or corporate finance advisory services or transaction in respect of the securities in this report. He/she has not and will not receive any compensation directly or indirectly linked to the performance of the securities of the subject corporation(s) from the time of the publication of this report either.